China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
 - EconoTimes)
MONTREAL, May 01, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.
At the time of approval of EGRIFTA® on November 10, 2010, the FDA requested that the company conduct two large safety clinical trials.
The FDA determined that these two large-scale post-approval clinical trials are no longer required as the current labeling adequately reflects the safety profile of EGRIFTA®. The FDA also concluded that the size of the HIV patient population with lipodystrophy did not make such a requirement feasible.
In its most recent audited financial statements, for the year ended November 30, 2017, Theratechnologies estimated that the post-approval commitments would require an additional investment of US$13 million, which will no longer be required.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236
